Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment

References

• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May;83(5):584–594.
   PubMed Web of Science ®Google Scholar
• Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol Off J Am Soc Clin Oncol. 2017 Dec;35(34):3823–3829.
   PubMed Web of Science ®Google Scholar
• Wang S, Tang J, Sun T, et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci Rep. 2017 May;7(1):1339.
   PubMedGoogle Scholar
• Riaz SP, Lüchtenborg M, Coupland VH, et al. Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer. 2012 Mar;75(3):280–284.
   PubMed Web of Science ®Google Scholar
• Rybarczyk-Kasiuchnicz A, Ramlau R. Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years. Kardiochirurgia i torakochirurgia Pol = Polish. J Cardio-thoracic Surg. 2018 Jun;15(2):119–124.
   Web of Science ®Google Scholar
• Aarts MJ, Aerts JG, Van Den Borne BE, et al. Comorbidity in patients with small-cell lung cancer: trends and prognostic impact. Clin Lung Cancer. 2015;16(4):282–291.
   PubMed Web of Science ®Google Scholar
• van Meerbeeck JP, Fennell DA, De Ruysscher DKM. Small-cell lung cancer. Lancet. 2011 Nov;378(9804):1741–1755.
   PubMed Web of Science ®Google Scholar
• Stahel RA, Ginsberg R, Havemann K, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer. 1989. https://doi.org/10.1016/0169-5002(89)90156-6.
   Google Scholar
• Shang X, Lin J, Li Z, Wang H. Radiotherapy may improve survival of ES-SCLC with distant metastasis only for patients with one metastatic site: A population-based study. Oncol Lett. 2020;19(1):139–146.
   PubMed Web of Science ®Google Scholar
• Dómine M, Moran T, Isla D, et al. SEOM clinical guidcaelines for the treatment of small-cell lung cancer (SCLC) (2019). Clin Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex. 2020 Feb;22(2):245–255.
   Google Scholar
• Comella P, Frasci G, De Cataldis G, et al. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Br J Cancer. 1996 Dec;74(11):1805–1811.
   PubMed Web of Science ®Google Scholar
• Haddadin S, Perry MC. History of small-cell lung cancer. Clin Lung Cancer. 2011 Mar;12(2):87–93.
   PubMed Web of Science ®Google Scholar
• Früh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013. DOI:https://doi.org/10.1093/annonc/mdt178
   Google Scholar
• Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: american society of clinical oncology endorsement of the American college of chest physicians guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2015 Dec;33(34):4106–4111.
   PubMed Web of Science ®Google Scholar
• Dingemans AC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32(7):839–853.
   PubMed Web of Science ®Google Scholar
• Bianco A, Malapelle U, Rocco D, Perrotta F, Mazzarella G. Targeting immune checkpoints in non small cell lung cancer. Curr Opin Pharmacol. 2018 Jun;40:46-50. Epub 2018 Mar 9. PMID: 29525401.
   Google Scholar
• Perrotta F, Rocco D, Vitiello F, et al. Immune checkpoint blockade for advanced NSCLC: a new landscape for elderly patients. Int J Mol Sci. 2019;20(9):2258.
   Web of Science ®Google Scholar
• FDA approves atezolizumab for extensive-stage small cell lung cancer. Case medical research. 2019.
   Google Scholar
• Union Register of medicinal products - Tecentriq - Public health - European Commission. 2020. Available from: https://ec.europa.eu/health/documents/community-register/html/reg_hum_act.htm?sort=a
   Google Scholar
• FDA approves durvalumab for extensive-stage small cell lung cancer. Case medical research. 2019.
   Google Scholar
• Union Register of medicinal products - Imfinzi - Public health - European Commission. 2020. Available from: https://ec.europa.eu/health/documents/community-register/html/reg_hum_act.htm?sort=a
   Google Scholar
• Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer. ClinicalTrials.gov Identifier: NCT04731909. Available from: https://clinicaltrials.gov/ct2/show/NCT04731909
   Google Scholar
• A study of atezolizumab plus carboplatin and etoposide with or without tiragolumab in patients with untreated extensive-stage small cell lung cancer. (SKYSCRAPER-02). ClinicalTrials.gov Identifier: NCT04256421; Available from:https://www.clinicaltrials.gov/ct2/show/NCT04256421
   Google Scholar
• Rodriguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J Clin Oncol. 2020 May;20(38):9503. 15_suppl)
   Google Scholar
• Liu SV, Reck M, Mansfield AS, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619–630.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. The Lancet. 2019 Nov;394(10212):1929–1939.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol Off J Am Soc Clin Oncol. 2020 Jul;38(21):2369–2379.
   PubMed Web of Science ®Google Scholar
• Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based ChemotherapyClinicalTrials.gov Identifier: NCT03670056. Available from: https://clinicaltrials.gov/ct2/show/NCT03670056
   Google Scholar
• A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) NCT03670056. Available from: https://clinicaltrials.gov/ct2/show/NCT03670056
   Google Scholar
• Ready N, Farago AF, de Braud F, et al. Third-line nivolumab monotherapy in recurrent SCLC: checkMate 032. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2019 Feb;14(2):237–244.
   Google Scholar
• Perez BA, Kim S, Wang M, et al. Prospective single-arm phase 1 and 2 study: ipilimumab and nivolumab with thoracic radiation therapy after platinum chemotherapy in extensive-stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 2021 Feb;109(2):425–435.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Park K, Govindan R, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: checkmate 451. J Clin Oncol Off J Am Soc Clin Oncol. 2021 Mar;39(12):1349–1359. JCO2002212.
   Google Scholar
• Malhotra J, Nikolinakos P, Leal T, et al. A phase i/ii study of rovalpituzumab tesirine in combination with nivolumab ± ipilimumab in patients with previously treated extensive-stage small cell lung cancer. J Thorac Oncol. 2021;S1556-0864(21)01745-7. [published online ahead of print, 2021 Feb 27]
   Google Scholar
• Ott P, Felip E, Hiret S, et al. OA05.01 pembrolizumab in patients with extensive-stage small cell lung cancer: updated survival results from KEYNOTE-028. J Thorac Oncol [Internet]. 2017;12(1):S259. Available from.
   Google Scholar
• A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC. ClinicalTrials.gov Identifier: NCT03963414. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT03963414
   Google Scholar
• Leal T, Wang Y, Dowlati A, et al. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. J Clin Oncol. 2020. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.9000.
   Google Scholar
• Owonikoko TK, Kim HR, Govindan R, et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): results from the double-blind, rando. Ann Oncol. 2019;30:ii77.
   PubMedGoogle Scholar
• Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC). J Thorac Oncol. 2018;13(9):1393–1399.
   Google Scholar
• Chung HC, Lopez-Martin JA, Kao SC-H, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. J Clin Oncol. 2018 May;36(36):8506. 15_suppl):
   Google Scholar
• Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. . J Thorac Oncol. 2020;15(4):618–627.
   Google Scholar
• Bristol Myers Squibb Statement on Opdivo (nivolumab) Small Cell Lung Cancer U.S. Indication. 2020. p. 1–9. Available from: https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Statement-on-Opdivo-nivolumab-Small-Cell-Lung-Cancer-US-Indication/default.aspx
   Google Scholar
• Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US. 2021. Available from: https://www.merck.com/news/merck-provides-update-on-keytruda-pembrolizumab-indication-in-metastatic-small-cell-lung-cancer-in-the-us/
   Google Scholar
• Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer ClinicalTrials.gov Identifier: NCT04012606. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT04012606
   Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 Dec;379(23):2220–2229.
   PubMed Web of Science ®Google Scholar
• Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer (PAVE). ClinicalTrials.gov Identifier: NCT03568097. https://www.clinicaltrials.gov/ct2/show/NCT03568097. 2018. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01895522/full
   Google Scholar
• A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley). Clinicaltrials.gov. 2015. p. 2015–2017. Available from: https://clinicaltrials.gov/show/NCT02554812
   Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensivedisease-small-cell lungcancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75–83.
   Web of Science ®Google Scholar
• Arriola E, Wheater M, Galea I, et al. Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. J Thorac Oncol. 2016;11(9):1511–1521.
   Web of Science ®Google Scholar
• Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy. NCT03670056. 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03670056
   Google Scholar
• Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):51–65.
   PubMed Web of Science ®Google Scholar
• Nigro E, Imperlini E, Scudiero O, et al. Differentially expressed and activated proteins associated with non small cell lung cancer tissues. Respir Res. 2015;16(1):1.
   PubMedGoogle Scholar
• Cattaneo F, Guerra G, Parisi M, et al. Expression of Formyl-peptide receptors in human lung carcinoma. Anticancer Res. 2015;35(5):2769–2774.
   PubMed Web of Science ®Google Scholar
• Nigro E, Perrotta F, Monaco ML, et al. Implications of the adiponectin system in non-small cell lung cancer patients: a case-control study. Biomolecules. 2020 Jun;10(6):6.
   Web of Science ®Google Scholar
• Bonanno L, Pavan A, M V D, et al. The role of immune microenvironment in small-cell lung cancer: distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. Eur J Cancer. 2018 Sep;101:191–200.
   PubMed Web of Science ®Google Scholar
• Song Y, Sun Y, Sun T, et al. Comprehensive bioinformatics analysis identifies tumor microenvironment and immune-related genes in small cell lung cancer. Comb Chem High Throughput Screen. 2020;23(5):381–391.
   PubMed Web of Science ®Google Scholar
• Pavan A, Attili I, Pasello G, et al. Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges. J Immunother Cancer. 2019 Aug;7(1):205.
   PubMed Web of Science ®Google Scholar
• Nigro E, Stiuso P, Matera MG, et al. The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549cells and oxidative stress involvement. Pulm Pharmacol Ther. 2019;55:25–30.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Small Cell Lung Cancer. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
   Google Scholar
• Lee HT, Lee JY, Lim H, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep. 2017;7(1):5532.
   PubMed Web of Science ®Google Scholar
• Rocco D, Malapelle U, Del Re M, et al. Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. Expert Opin Drug Metab Toxicol. 2020 Feb;16(2):87–96.
   PubMed Web of Science ®Google Scholar
• Rocco D, Gravara LD, Gridelli C. The new immunotherapy combinations in the treatment of advanced non-small cell lung cancer: reality and perspectives. Curr Clin Pharmacol. 2020;15(1):11–19.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010Oct;375:473–484.
   PubMed Web of Science ®Google Scholar
• Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016 Nov;34(31):3740–3748.
   PubMed Web of Science ®Google Scholar
• Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 2016 Feb 1;18(2):195–205.
   PubMed Web of Science ®Google Scholar
• Maleki Vareki S, Garrigós C, Duran I. Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol. 2017 Aug;116:116–124.
   PubMed Web of Science ®Google Scholar
• Yu W, Hua Y, Qiu H, et al. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis. 2020;11(7):506.
   PubMed Web of Science ®Google Scholar
• Perrotta F, Nankivell M, Adizie B, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for PD-L1 testing in non-small cell lung cancer. Chest. 2020 May. https://doi.org/10.1016/j.chest.2020.04.059
   Google Scholar
• Gridelli C, Ardizzoni A, Barberis M, et al. Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an experts panel meeting of the Italian association of thoracic oncology. Transl Lung Cancer Res. 2017 Jun;6(3):373–386.
   PubMed Web of Science ®Google Scholar
• Ortega-Franco A, Ackermann C, Paz-Ares L, et al. First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions. ESMO Open. 2021 Feb;6(1):100003.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–895.
   PubMed Web of Science ®Google Scholar
• Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell [Internet]. 2021 Mar 8;39(3):346–360. e7. Available from.
   PubMed Web of Science ®Google Scholar
• Bianco A, Perrotta F, Barra G, et al. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer. Int J Mol Sci. 2019 Oct;20(19):4931.
   Web of Science ®Google Scholar
• Pezzuto F, Fortarezza F, Lunardi F, et al. Are there any theranostic biomarkers in small cell lung carcinoma? J Thorac Dis. 2019Jan;11(Suppl 1):S102–12.
   PubMedGoogle Scholar
• Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019 May;19(5):289–297.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Sen T, Rudin CM. Targeted therapies and biomarkers in small cell lung cancer. Front Oncol. 2020;10:741.
   PubMed Web of Science ®Google Scholar
• Broll K, Richter G, Pauly S, et al. CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am J Clin Pathol. 2001 Apr;115(4):543–549.
   PubMed Web of Science ®Google Scholar
• Kienzle G, von Kempis J. CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. Int Immunol. 2000 Jan;12(1):73–82.
   PubMed Web of Science ®Google Scholar
• Cheuk ATC, Mufti GJ, Guinn B. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Available from Cancer Gene Ther. 2004;113:215–226.
   PubMed Web of Science ®Google Scholar
• Chen S, Lee LF, Fisher TS, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a Poorly Immunogenic Tumor Model. Cancer Immunol Res. 2015;3(2):149–160.
   Web of Science ®Google Scholar
• Tolcher AW, Sznol M, Hu-Lieskovan S, et al. Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors. Clin Cancer Res. 2017;23(18):5349–5357.
   Web of Science ®Google Scholar
• Zingoni A, Sornasse T, Cocks BG, et al. Cross-Talk between Activated Human NK Cells and CD4 + T Cells via OX40-OX40 Ligand Interactions. J Immunol. 2004. https://doi.org/10.4049/jimmunol.173.6.3716
   Google Scholar
• Kashiwakura J, Yokoi H, Saito H, et al. Proliferation by Direct Cross-Talk between OX40 ligand on human mast cells and ox40 on human t cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol. 2004. https://doi.org/10.4049/jimmunol.173.8.5247
   Google Scholar
• Imura A, Hori T, Imada K, et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med. 1996 May;183(5):2185–2195.
   PubMed Web of Science ®Google Scholar
• Massarelli E, Lam VK, Parra ER, et al. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. J Immunother Cancer. 2019;7(1):351.
   PubMed Web of Science ®Google Scholar
• Croft M. Control of Immunity by the TNFR-related molecule OX40 (CD134). Ann Rev Immunol. 2010;28(1):57–78.
   PubMedGoogle Scholar
• A study exploring the safety and efficacy of incagn01949 in combination with immune therapies in advanced or metastatic malignanciesClinicaltrials Gov. 2019; October 2, 2017-Jul-20. Available from https://clinicaltrials.gov/show/NCT03241173
   Google Scholar
• Kim JD, Choi BK, Bae JS, et al. Cloning and characterization of GITR ligand. Genes Immun. 2003 Dec;4(8):564–569.
   PubMed Web of Science ®Google Scholar
• Zappasodi R, Sirard C, Li Y, et al. Rational design of anti-GITR-based combination immunotherapy. Nat Med. 2019/04/29. 2019 May 25(5):759–766. .
   PubMed Web of Science ®Google Scholar
• Cohen AD, Schaer DA, Liu C, et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One. 2010 May;5(5):e10436.
   PubMed Web of Science ®Google Scholar
• Buzzatti G, Dellepiane C, Del Mastro L. New emerging targets in cancer immunotherapy: the role of GITR. ESMO Open 2020Aug; 4 \(Suppl 3):e000738–e000738.
   PubMedGoogle Scholar
• Koon HB, Shepard DR, Merghoub T, et al. First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors. J Clin Oncol. 2016;34(15_suppl):3017.
   Web of Science ®Google Scholar
• Shan C, Li X, Zhang J. Progress of immune checkpoint LAG‑3 in immunotherapy (Review). Oncol Lett. 2020 Available from;20(5):207.
   PubMed Web of Science ®Google Scholar
• Visan I. New ligand for LAG-3. Nat Immunol. 2019;202:111.
   Web of Science ®Google Scholar
• He Y, Yu H, Rozeboom L, et al. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol. 2017 May;12(5):814–823.
   PubMed Web of Science ®Google Scholar
• Du H, Yi Z, Wang L, et al. The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy. Int Immunopharmacol. 2020;78:106113.
   PubMed Web of Science ®Google Scholar
• Chen X, Lu P-H, Liu L, et al. TIGIT negatively regulates inflammation by altering macrophage phenotype. Immunobiology 2016 Jan;221(1):48–55.
   PubMed Web of Science ®Google Scholar
• Harjunpää H, Guillerey C. TIGIT as an emerging immune checkpoint. Clinical & Experimental Immunology. 2020;200(2):108–119. Clinic Exp Immunology.
   PubMed Web of Science ®Google Scholar
• Xu Y, Cui G, Jiang Z, et al. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. Oncol Lett [ 2019/01/09. 2019 Mar;17(3):2960–2968. :
   PubMed Web of Science ®Google Scholar
• Owen DH, Giffin MJ, Bailis JM, et al. DLL3: an emerging target in small cell lung cancer. Available from J Hematol Oncol. 2019;121:61.
   PubMed Web of Science ®Google Scholar
• Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2020;27(5):1526–1537.
   PubMed Web of Science ®Google Scholar
• Smit M-AD, Borghaei H, Owonikoko TK, et al. Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC). J Clin Oncol [Internet] 2019 May 20;37(15_suppl): TPS8577–TPS8577. Available from: https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS8577
   Google Scholar
• Chu QS-C, van Herpen C, Leighl NB, et al. Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC). Ann Oncol. 2017;28:v539.
   PubMedGoogle Scholar